Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Patrick W. Gould
Observed names:
P. Gould,
Patrick Gould
Observed institutions:
Boston Children's Hospital,
Harvard University,
Columbia University Irving Medical Center,
Columbia University,
University of Pennsylvania
ORCID:
0000-0002-5950-4559
Observed ORCID:
0000-0002-5950-4559
OpenAlex ID:
A5060935112
Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis
2019
·
Audrey Dionne
, Jane C. Burns
, et al.
·
PEDIATRICS
·
99
PDF
Adipocytokines and Associations With Abnormal Body Composition in Rheumatoid Arthritis
2021
·
Joshua F. Baker
, Patricia Katz
, et al.
·
Arthritis Care & Research
·
27
PDF
Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms
2021
·
Olha Halyabar
, Kevin G. Friedman
, et al.
·
Pediatric Rheumatology
·
25
PDF
Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations With Disease Characteristics, Body Composition, and Physical Functioning
2020
·
Patrick W. Gould
, Babette S. Zemel
, et al.
·
The Journal of Rheumatology
·
15
Impact of Socioeconomic Status on Outcomes of Patients with Kawasaki Disease
2019
·
Audrey Dionne
, Emily M. Bucholz
, et al.
·
The Journal of Pediatrics
·
15
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs
2022
·
Patrick Gould
, Tasnim Salam
, et al.
·
JAMA Network Open
·
8
PDF
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2025
·
Edward R. Scheffer Cliff
, Guido D. Pelaez
, et al.
·
Clinical Cancer Research
·
3
Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms
2021
·
Elif Seda Selamet Tierney
, Kyle Runeckles
, et al.
·
The Journal of Pediatrics
·
3
Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist
2023
·
Holly Fernandez Lynch
, Tasnim Salam
, et al.
·
JAMA Network Open
·
2
PDF
Data from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2026
·
Edward R. Scheffer Cliff
, Guido D. Pelaez
, et al.
Supplemental Table 1 from Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
2026
·
Edward R. Scheffer Cliff
, Guido D. Pelaez
, et al.
Primary Treatment Intensification With Steroids Versus Infliximab in Patients With Coronary Artery Aneurysms at Time of Diagnosis
2018
·
A. Dionne
, J. Burns
, et al.
·
Canadian Journal of Cardiology
Show more works
View as search
Works count:
12
Citation count:
197
H-index:
6
I10-index:
5
Year
Topic
Type
